NCT01382706 - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2011

Primary Completion Date

July 15, 2013

Study Completion Date

December 15, 2017

Conditions

Recurrent Bladder CancerStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder

Interventions

DRUG

docetaxel

Given IV

DRUG

lapatinib ditosylate

Given PO

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

fluorescence in situ hybridization

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

USC/Norris Comprehensive Cancer Center, Los Angeles